8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
Titel:
8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
Auteur:
Moreno, V. Vieito Villar, M. Sepulveda Sanchez, J.M. Galvao, V. Hernández Guerrero, T. Doger, B. Saavedra, O. Carlo Stella, C. Michot, J-M. Italiano, A. Magagnoli, M. Carpio, C. Sarmiento, R. Amoroso, B. Aronchik, I. Filvaroff, E. Hanna, B. Pinto, A. Nikolova, Z. Braña, I.